Hans-Georg Rammensee

Hans-Georg Rammensee's AcademicInfluence.com Rankings

Law

#1614

World Rank

#2025

Historical Rank

Common Law

#44

World Rank

#49

Historical Rank

law Degrees

Hans-Georg Rammensee

Biology

#1762

World Rank

#2863

Historical Rank

Immunology

#143

World Rank

#150

Historical Rank

biology Degrees

Download Badge

Law
Biology

Hans-Georg Rammensee's Degrees

PhD Immunology University of Tübingen
Doctorate Medicine University of Tübingen

Why Is Hans-Georg Rammensee Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hans-Georg Rammensee is a German immunologist and cancer researcher. He has been Chair Professor and Head of the Department of Immunology at the University of Tübingen since 1996. Rammensee has contributed essentially to the research fields of MHC biology and tumor immunology and to the development of cancer immunotherapies.

(See a Problem?)

Hans-Georg Rammensee's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules (1991) (2502)
SYFPEITHI: database for MHC ligands and peptide motifs (1999) (2391)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) (1612)
MHC ligands and peptide motifs: first listing (2004) (956)
Peptides naturally presented by MHC class I molecules. (1993) (829)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival (2012) (787)
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells (1990) (771)
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. (2002) (733)
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding (2002) (641)
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins (2005) (638)
Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. (1985) (614)
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine (1989) (606)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. (2003) (532)
The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway* (2002) (530)
Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (518)
Exact prediction of a natural T cell epitope (1991) (473)
Clonal anergy induced in mature Vβ6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells (1989) (460)
Cellular peptide composition governed by major histocompatibility complex class I molecules (1990) (439)
Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. (1999) (430)
The heat shock protein gp96 induces maturation of dendritic cells and down‐regulation of its receptor (2000) (414)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? (2009) (410)
MHC Ligands and Peptide Motifs (1998) (406)
Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products (2001) (400)
Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis (2000) (391)
Chemistry of peptides associated with MHC class I and class II molecules. (1995) (385)
Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 (1995) (372)
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition (2020) (355)
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. (1998) (355)
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. (1999) (339)
Tumor-associated MICA is shed by ADAM proteases. (2008) (338)
A role for the proteasome regulator PA28α in antigen presentation (1996) (333)
Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding (2005) (324)
Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands (1996) (312)
Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides (1998) (306)
Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. (2012) (290)
Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. (1999) (290)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism (2008) (286)
Two new proteases in the MHC class I processing pathway (2000) (283)
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients (2009) (274)
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. (1996) (272)
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein (2003) (269)
Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast (1991) (266)
Contribution of Proteasomal β-Subunits to the Cleavage of Peptide Substrates Analyzed with Yeast Mutants* (1998) (263)
Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. (1998) (253)
Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo1 (2005) (240)
Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. (2000) (235)
On the nature of peptides involved in T cell alloreactivity (1991) (228)
Several HLA alleles share overlapping peptide specificities. (1995) (224)
Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. (1990) (217)
Nonclassical HLA-G molecules are classical peptide presenters (1996) (215)
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. (2002) (212)
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA (2008) (211)
Identification of classical minor histocompatibility antigen as cell-derived peptide (1990) (208)
PAProC: a prediction algorithm for proteasomal cleavages available on the WWW (2001) (204)
Triggering Receptor Expressed on Myeloid Cells-1 in Neutrophil Inflammatory Responses: Differential Regulation of Activation and Survival (2004) (203)
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. (2003) (201)
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. (2000) (199)
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. (2011) (197)
More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer (2011) (190)
Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. (1994) (187)
The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules (1991) (185)
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. (2008) (183)
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. (2002) (182)
Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA (2005) (180)
Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. (2002) (169)
The peptide binding motif of the disease associated HLA‐DQ (α 1* 0501, β 1* 0201) molecule (1996) (167)
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines (2002) (166)
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. (2012) (165)
MHC molecules as peptide receptors. (1993) (163)
HLA-Encoded Genetic Predisposition in IDDM: DR4 Subtypes May Be Associated With Different Degrees of Protection (1997) (161)
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies (2000) (159)
Limit of T cell tolerance to self proteins by peptide presentation. (1990) (151)
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent (2007) (151)
Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells (1997) (148)
HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. (2001) (146)
Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach (2000) (146)
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2014) (146)
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines (2004) (143)
Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Gp96 Amplifies Innate and Adaptive Immune Responses* (2006) (141)
Immunostimulating capacities of stabilized RNA molecules (2004) (140)
Allele-specific peptide ligand motifs of HLA-C molecules. (1993) (139)
Efficiency of peptides and lipopeptides for in vivo priming of virus‐specific cytotoxic T cells (1991) (136)
Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9/Vδ2 T cells in tumor immunity (1997) (135)
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. (1997) (135)
Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules (2004) (134)
Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1 (2002) (130)
The endoplasmic reticulum‐resident stress protein gp96 binds peptides translocated by TAP (1997) (128)
Moderate degradation does not preclude microarray analysis of small amounts of RNA. (2003) (128)
Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules (1995) (124)
The Human 26 S and 20 S Proteasomes Generate Overlapping but Different Sets of Peptide Fragments from a Model Protein Substrate* (2000) (122)
Evidence from in vitro studies that tolerance to self antigens is MHC-restricted (1984) (122)
Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface*S (2007) (120)
HLA-A2 subtypes are functionally distinct in peptide binding and presentation (1995) (120)
Nucleosome, the Main Autoantigen in Systemic Lupus Erythematosus, Induces Direct Dendritic Cell Activation via a MyD88-Independent Pathway: Consequences on Inflammation1 (2005) (118)
Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA1 (2008) (118)
The immunopeptidomic landscape of ovarian carcinomas (2017) (116)
Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA (2006) (116)
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. (2007) (115)
Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay (1997) (115)
Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. (2014) (114)
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. (2010) (113)
Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). (1997) (113)
An open-source computational and data resource to analyze digital maps of immunopeptidomes (2015) (110)
Stress proteins and immunity mediated by cytotoxic T lymphocytes. (1999) (110)
The SysteMHC Atlas project (2017) (109)
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy (2004) (109)
A role for the proteasome regulator PA28alpha in antigen presentation. (1996) (108)
MAPPP: MHC class I antigenic peptide processing prediction. (2003) (108)
Neurological symptoms in patients with biopsy proven celiac disease (2009) (107)
Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions (2007) (104)
Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. (2006) (100)
Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer (2009) (100)
Influences of Transporter Associated with Antigen Processing (TAP) on the Repertoire of Peptides Associated with the Endoplasmic Reticulum–resident Stress Protein gp96 (1997) (100)
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity (2021) (99)
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals (2021) (99)
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. (2015) (97)
Qa-2 molecules are peptide receptors of higher stringency than ordinary class I molecules (1993) (97)
gp96—The immune system's Swiss army knife (2000) (94)
Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling (2004) (94)
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy (2014) (94)
Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome‐dependent and ‐independent proteolytic activities (1998) (93)
HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis (2020) (93)
Peptide motifs of closely related HLA class I molecules encompass substantial differences (1992) (93)
A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. (2001) (92)
HLA ligandome tumor antigen discovery for personalized vaccine approach (2013) (92)
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire (2020) (92)
The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells (2000) (91)
Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behćet's disease. (1995) (89)
Plasmid DNA- and messenger RNA-based anti-cancer vaccination. (2008) (89)
Ex vivo generation of human cytomegalovirus‐specific cytotoxic T cells by peptide‐pulsed dendritic cells (2001) (89)
Human platelets express heat shock protein receptors and regulate dendritic cell maturation. (2002) (88)
Priming of cytotoxic T lymphocytes by five heat‐aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses (1997) (86)
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. (2013) (86)
Towards patient‐specific tumor antigen selection for vaccination (2002) (86)
Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen. (1984) (86)
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. (2003) (86)
The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. (2013) (85)
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. (2009) (85)
Features of TAP‐independent MHC class I ligands revealed by quantitative mass spectrometry (2008) (84)
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy (2005) (81)
Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide (1991) (81)
TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen (2013) (81)
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons (2013) (80)
Characterization of the ribonuclease activity on the skin surface (2006) (79)
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma (2019) (78)
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis (2004) (78)
The Role of Peptides in T Cell Alloreactivity Is Determined by Self–Major Histocompatibility Complex Molecules (2000) (77)
Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas (2006) (77)
Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. (1984) (76)
Identification of multiple HIV‐1 cytotoxic T‐cell epitopes presented by human leukocyte antigen B35 molecules (1996) (74)
Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. (1993) (74)
Quantitative Analysis of Prion-Protein Degradation by Constitutive and Immuno-20S Proteasomes Indicates Differences Correlated with Disease Susceptibility1 (2004) (74)
Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression (1991) (73)
Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. (2009) (72)
Naturally Presented Peptides on Major Histocompatibility Complex I and II Molecules Eluted from Central Nervous System of Multiple Sclerosis Patients* (2009) (71)
Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices (2017) (70)
Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. (1984) (69)
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy (2021) (69)
Primary blood neutrophils express a functional cell surface Toll‐like receptor 9 (2013) (68)
The peptide binding motif of the disease associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule. (1996) (68)
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells (2008) (68)
Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. (1996) (67)
Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres 1 (2003) (67)
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance (2017) (66)
A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells (1998) (66)
Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients (2012) (65)
Stimulation of TNFα expression by hyperosmotic stress (2002) (64)
Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1 (1994) (63)
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia (2012) (62)
Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum (1997) (62)
A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing (2003) (62)
Induction of HA‐1‐specific cytotoxic T‐cell clones parallels the therapeutic effect of donor lymphocyte infusion (2002) (61)
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy (2015) (60)
Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. (1996) (60)
Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 (2006) (60)
Inhibitory MHC class I receptors on γδ T cells in tumour immunity and autoimmunity (2000) (60)
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient (2016) (60)
Effective Chemokine Secretion by Dendritic Cells and Expansion of Cross-Presenting CD4−/CD8+ Dendritic Cells Define a Protective Phenotype in the Mouse Model of Coxsackievirus Myocarditis (2008) (59)
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells (2007) (59)
An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. (2014) (58)
MHC class II‐associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation (1998) (58)
TLR2/TLR4-Independent Neutrophil Activation and Recruitment upon Endocytosis of Nucleosomes Reveals a New Pathway of Innate Immunity in Systemic Lupus Erythematosus1 (2006) (58)
The regulatory landscape for actively personalized cancer immunotherapies (2013) (58)
Peptide motifs of HLA-A1,-A11,-A31, and-A33 molecules (1994) (58)
Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen (2007) (57)
64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET (2015) (57)
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors (2013) (57)
Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. (1992) (56)
Restricted recognition of β2-microglobulin by cytotoxic T lymphocytes (1986) (56)
Cutting Edge: Characterization of Allorestricted and Peptide-Selective Alloreactive T Cells Using HLA-Tetramer Selection1 (2001) (55)
Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer (2016) (55)
Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. (2009) (55)
Alloreactivity as a source of high avidity peptide-specific human CTL. (1999) (54)
Identification of non-mutated neoantigens presented by TAP-deficient tumors (2018) (53)
Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. (2006) (53)
Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA‐B44 supertype (2008) (53)
Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing (1994) (53)
Analysis of allele-specific contact sites of natural HLA-DR17 ligands. (1994) (53)
NKp80 defines and stimulates a reactive subset of CD8 T cells. (2009) (52)
The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy (2004) (52)
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. (1997) (52)
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity (2021) (52)
Dendritic Cell Aggresome-Like-Induced Structure Formation and Delayed Antigen Presentation Coincide in Influenza Virus-Infected Dendritic Cells1 (2005) (51)
Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. (1997) (51)
Identification of a new HLA‐A*0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen (2000) (51)
Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs (2004) (51)
HLA ligand profiles of primary renal cell carcinoma maintained in metastases (2009) (50)
Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. (2000) (50)
Peptide motifs of HLA-B35 and-B37 molecules (2004) (50)
Nucleosome‐induced neutrophil activation occurs independently of TLR9 and endosomal acidification: Implications for systemic lupus erythematosus (2011) (49)
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. (2018) (49)
Suppression of cell‐mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt‐1+Lyt−2+ T cells of stimulator‐strain origin (1982) (48)
Analysis of tumor antigen‐specific T cells and antibodies in cancer patients treated with radiofrequency ablation (2011) (48)
The peptide vaccine of the future. (2020) (48)
Peptide motifs of HLA-B58, B60, B61, and B62 molecules (2004) (47)
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. (2018) (47)
PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma (2019) (47)
The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI. (1996) (47)
Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. (2002) (47)
Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. (2015) (47)
Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation (2011) (46)
Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. (2000) (46)
“Electronic nose” detects major histocompatibility complex-dependent prerenal and postrenal odor components (2001) (45)
The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. (2013) (45)
Characterizing the N-Terminal Processing Motif of MHC Class I Ligands1 (2008) (44)
A tissue-based draft map of the murine MHC class I immunopeptidome (2018) (44)
Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. (1997) (44)
Glycan side chains on naturally presented MHC class II ligands. (2005) (43)
Natural ligand motifs of H-2E molecules are allele specific and illustrate homology to HLA-DR molecules. (1995) (43)
Dipeptides catalyze rapid peptide exchange on MHC class I molecules (2014) (43)
A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. (2008) (42)
Allo‐ and self‐restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire (1998) (42)
Insulin-mediated cortical activity in the slow frequency range is diminished in obese mice and promotes physical inactivity (2009) (42)
Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes (2004) (41)
Immune Evasion by Yersinia enterocolitica: Differential Targeting of Dendritic Cell Subpopulations In Vivo (2010) (41)
Gαs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells (2019) (40)
Antigen presentation--recent developments. (1996) (40)
Veto function in vitro and in vivo. (1989) (40)
Stimulation of TNF alpha expression by hyperosmotic stress. (2002) (40)
Personalized cancer vaccines: adjuvants are important, too (2018) (40)
Antigen specific suppression of T-cell responses - the veto concept. (1985) (39)
Identification of Chlamydia pneumoniae-Derived Mouse CD8 Epitopes (2002) (39)
High frequency of human cytomegalovirus (HCMV)-specific CD8+-T cells detected in a healthy CMV-seropositive donor (2002) (39)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2018) (38)
Of volatiles and peptides: in search for MHC-dependent olfactory signals in social communication (2014) (38)
Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. (2018) (37)
Toll‐like receptors 2 and 4 impair insulin‐mediated brain activity by interleukin‐6 and osteopontin and alter sleep architecture (2012) (37)
The T‐Cell Receptor for Antigen in T‐Cell Development and Repertoire Selection (1988) (37)
HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. (2013) (36)
TGF‐β‐independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells (1999) (35)
Comparative Analysis of Volatile Constituents from Mice and their Urine (2006) (35)
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy (2017) (35)
Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment (2002) (35)
Perfect use of imperfection (2000) (35)
Nucleosomes induce lymphocyte necrosis (2003) (34)
A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells (2009) (34)
Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma (2018) (34)
Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. (2005) (34)
Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application (2013) (34)
Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. (2008) (34)
Motif of HLA-B*3503 peptide ligands (2004) (34)
Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. (2003) (33)
Identification of a naturally processed cyclin D1 T‐helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry (2004) (33)
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas (2005) (33)
Glycoprotein 96–activated dendritic cells induce a CD8-biased T cell response (2005) (33)
Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire (2004) (33)
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer (2019) (33)
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. (1997) (32)
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy (2015) (32)
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia (2017) (32)
MAGED4 – expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue (2005) (31)
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy (2018) (31)
Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. (2001) (31)
Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes (2004) (31)
High frequencies of functionally impaired cytokeratin 18‐specific CD8+ T cells in healthy HLA‐A2+ donors (2005) (31)
Thymocyte clones from 14-day mouse embryos. I. State of T cell receptor genes, surface markers, and growth requirements (1987) (31)
The making of the dominant MHC class I ligand SYFPEITHI (1998) (31)
Leishmania mexicana promastigotes induce cytotoxic T lymphocytes in vivo that do not recognize infected macrophages (1993) (31)
Immunotherapy of renal cell carcinoma (2006) (30)
High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules (2019) (30)
Targeting tumor-resident mast cells for effective anti-melanoma immune responses. (2019) (30)
SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition (2020) (30)
Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I‐restricted antigen presentation (1996) (30)
Human CD4+ T Cells Displaying Viral Epitopes Elicit a Functional Virus-Specific Memory CD8+ T Cell Response1 (2007) (29)
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy (2016) (29)
Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. (1997) (29)
Both human and mouse cells expressing H-2Kb and ovalbumin process the same peptide, SIINFEKL. (1993) (29)
Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. (2019) (29)
SNEP: SNP-derived Epitope Prediction program for minor H antigens (2005) (29)
Analysis of a naturally occurring HLA class I-restricted viral epitope. (1994) (28)
Peptide analysis, stability studies, and structural modeling explain contradictory peptide motifs and unique properties of the NOD mouse MHC class II molecule H2‐Ag7 (2002) (28)
The HLA Ligand Atlas. A resource of natural HLA ligands presented on benign tissues (2019) (28)
T cell avidity determines the level of CTL activation (2004) (28)
T helper cell‐dependent induction of resting B cell differentiation need not require cognate cell interactions (1988) (28)
Erratum: An algorithm for the prediction of proteasomal cleavages (Journal of Molecular Biology (2000) 298 (417-427)) (2000) (27)
Phagocytosis of dying tumor cells by human peritoneal mesothelial cells (2011) (27)
Definition of peptide binding motifs amongst the HLA-A*30 allelic group. (2000) (27)
EpiToolKit—a web server for computational immunomics (2008) (26)
MHCquant: Automated and reproducible data analysis for immunopeptidomics. (2019) (26)
Peptide presentation and NK inhibition by HLA-G. (1999) (26)
Long-Term Immunity against Actual Poxviral HLA Ligands as Identified by Differential Stable Isotope Labeling1 (2008) (25)
Impact of curative radiotherapy on the immune status of patients with localized prostate cancer (2018) (25)
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized. (1997) (25)
Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient” (2016) (25)
A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation. (2003) (24)
MHC/peptide binding studies indicate hierarchy of anchor residues. (1993) (24)
A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. (1996) (24)
The molecular interactions with helper T cells which limit antigen‐specific B cell differentiation (1988) (24)
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer (2021) (24)
Quantitative Analysis of Mouse Urine Volatiles: In Search of MHC-Dependent Differences (2007) (24)
Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. (2011) (24)
In vitro Antiproliferative Effect of Helix aspersa Hemocyanin on Multiple Malignant Cell Lines (2014) (23)
Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer (2013) (23)
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies (2020) (23)
Hematopoietic Lineage-Restricted Minor Histocompatibility Antigen HA-1 in Graft-Versus-Leukemia Activity After Donor Lymphocyte Infusion (2004) (23)
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy (2020) (23)
Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells in vitro and in vivo (2005) (22)
Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation (2011) (22)
Identification of Naturally Processed Hepatitis C Virus-Derived Major Histocompatibility Complex Class I Ligands (2012) (22)
One-step single-chain Fv recombinant antibody-based purification of gp96 for vaccine development. (2000) (22)
Innate immune system favors emergency monopoiesis at the expense of DC‐differentiation to control systemic bacterial infection in mice (2015) (22)
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer (2019) (22)
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent (2009) (22)
Class I restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens. (1984) (22)
Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. (2010) (21)
Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. (2017) (21)
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy (2013) (21)
Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy (2016) (21)
Identification of HLA‐A2‐restricted epitopes of the tumor‐associated antigen MUC2 recognized by human cytotoxic T cells (1998) (21)
Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement1 (2009) (21)
Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. (2003) (20)
Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies* (2019) (20)
Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2020) (20)
The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis (1999) (20)
The European Regulatory Environment of RNA-Based Vaccines. (2017) (20)
Ligand motif of the autoimmune disease‐associated mouse MHC class II molecule H2‐As (2001) (20)
Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. (2008) (20)
Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction (2012) (20)
Peptide binding motifs of the MHC class I molecules (RT1.Al) of the Lewis rat (1997) (20)
Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation (2018) (20)
Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia (2008) (19)
Peptide motif of a cattle MHC class I molecule. (1995) (19)
Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T(HELPER) cells following stem cell transplantation. (2010) (19)
HLA-A26 subtype A pockets accommodate acidic N-termini of ligands (1998) (19)
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini (2016) (19)
Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing (1992) (19)
Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. (1998) (18)
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters (2015) (18)
Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man (1992) (18)
Isolation of human minor histocompatibility peptides. (1992) (18)
Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response (2019) (18)
Peptide motifs of HLA-B38 and B39 molecules (2004) (18)
Identification of Immunogenic Epitopes by MS/MS (2017) (18)
Human peripheral blood monuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro (2005) (18)
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer (2020) (18)
Immunology: Protein surgery (2004) (17)
Human Peripheral CD4+ Vδ1+ γδT Cells Can Develop into αβT Cells (2014) (17)
Mutual tolerization of histoincompatible lymphocytes (1987) (17)
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial (2020) (17)
Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft–host interaction (2016) (17)
Complexity of the histocompatibility-3 region in the mouse. (1983) (17)
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. (2016) (16)
Antileukemia T-cell responses in CLL – We don't need no aberration (2015) (16)
The role of peptide presentation in the physiological function of HLA-G. (1999) (16)
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy (2015) (16)
Masking of veto function in vivo by activated CD4+ T lymphocytes (1989) (16)
In vitro effect of molluscan hemocyanins on CAL-29 and T-24 bladder cancer cell lines. (2013) (16)
Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket (1996) (16)
Interaction of TLR 2 and TLR 4 Ligands with the N-terminal Domain of Gp 96 Amplifies Innate and Adaptive Immune Responses * (2006) (16)
Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity (2013) (15)
Alternative T cell receptor gene usage induced by self tolerance (1989) (15)
A distinctive peptide binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis (1997) (15)
Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis (2015) (15)
Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (2022) (15)
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups (2021) (14)
Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo (2006) (14)
Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design (2016) (14)
A prominent natural H-2 Kd ligand is derived from protein tyrosine kinase JAK1. (1993) (14)
Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models (2019) (14)
Role of anchor residues in peptide binding to three HLA-A26 molecules. (1999) (14)
Murine epidermal Langerhans cells express significant amounts of class I major histocompatibility complex antigens. (1989) (14)
CD4+ T cell-mediated immunity against prion proteins (2003) (13)
Molecular Modeling of Eluted Peptides from DQ6 Molecules (DQB1*0602 and DQB1*0604) Negatively and Positively Associated with Type 1 Diabetes (2002) (13)
Inhibition of interferon-gamma expression by osmotic shrinkage of peripheral blood lymphocytes. (2003) (13)
A self peptide naturally presented by both H-2Kb and H-2Kbm1 molecules demonstrates MHC restriction of self tolerance at the molecular level. (1992) (13)
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors (2005) (13)
Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer (2006) (13)
Pillars Article: Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules. Nature 1991. 351: 290–296. (2006) (13)
Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes. (1986) (13)
Comparison of the H-2Kk- and H-2Kkm1-restricted peptide motifs. (1993) (13)
Peptides made to order. (2006) (13)
Characterization of an HIV-1 p24gag epitope recognized by a CD8+ cytotoxic T-cell clone. (1997) (13)
Possible association of non-binding of HSP70 to HLA-DRB1 peptide sequences and protection from rheumatoid arthritis (2002) (12)
CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. (2005) (12)
Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA‐Peptide Multimer Staining Assay (2018) (12)
GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. (2018) (12)
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation (2020) (12)
Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome (2018) (12)
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia (2021) (12)
Targeting cytotoxic T cells to antigen‐specific B lymphocytes (1987) (12)
Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols (2017) (12)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2019) (12)
Immunoinformatics: bioinformatic strategies for better understanding of immune function. Introduction. (2003) (11)
Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmunity. (2000) (11)
The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells. (2005) (11)
Antibodies against the transferrin receptor block the induction of cytotoxic T lymphocytes. A new method for antigen‐specific negative selection in vitro (1985) (11)
Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro. (2005) (11)
Problem solving for tumor immunotherapy (2000) (11)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2018) (10)
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. (2006) (10)
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens (2017) (10)
Identification of T-cell epitopes using allele-specific ligand motifs. (1994) (10)
Monoclonal antibodies to transferrin receptor and assay of their biological effects. (1987) (10)
Immunology: Survival of the fitters (2002) (9)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (9)
Chair's Introduction (2008) (9)
Peptide motif of HLA-B*1510 (1999) (9)
TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. (1999) (9)
The MHC Genes (1997) (9)
Molecular Modeling of the Class I Human Histocompatibility Molecule HLA‐A2 Presenting an Allele‐Specific Nonapeptide from Influenza Matrix Protein (1992) (9)
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma (2020) (9)
HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients. (2018) (9)
The Peptide Vaccine of the Future (2021) (8)
Evolutionary Conserved Cathepsin E Substrate Specificity as Defined by N-Terminal and C-Terminal Sequencing of Peptide Pools (1997) (8)
Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus antibody test for the evaluation of cross-reactivity to endemic coronavirus antigens (2020) (8)
Polymorphism of minor histocompatibility genes in wild mice (2004) (8)
Legionella pneumophila down-regulates MHC class I expression of human monocytic host cells and thereby inhibits T cell activation (2005) (8)
MHC class I-restricted antigen processing--lessons from natural ligands. (1993) (8)
Identification of an Immunogenic HLA-A*0201-binding T-cell Epitope of the Transcription Factor PAX2 (2009) (8)
76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma (2012) (8)
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies (2017) (8)
The antigen self-presentation function of the cytotoxic T-cell clone 10BK.1 depends on reciprocal peptide presentation. (1994) (7)
The HLA-B* 1516 motif demonstrates HLA-B-specific P2 pocket characteristics (1998) (7)
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells (2017) (7)
The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek’s disease virus peptides by using an unprecedented binding motif (2021) (7)
miHA-match: computational detection of tissue-specific minor histocompatibility antigens (2012) (7)
Self tolerance of natural MHC class I ligands. (1993) (7)
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (7)
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications (2018) (6)
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function (2021) (6)
Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer (2021) (6)
Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens (2022) (6)
Interferon-induced expression of If-1h and If-1l alleles in Newcastle disease virus-infected mouse macrophages is associated with specific differences in viral gene transcription. (1998) (6)
Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus (2021) (6)
A conserved sequence in the mouse variable T cell receptor α recombination signal sequence 23‐bp spacer can affect recombination (2004) (6)
Integrin Activation Enables Sensitive Detection of Functional CD4+ and CD8+ T Cells: Application to Characterize SARS-CoV-2 Immunity (2021) (5)
Editorial: Novel Strategies for Anti-Tumor Vaccines (2020) (5)
Role of Macrophages in Uveal Melanoma (2007) (5)
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors (2021) (5)
Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL (2017) (5)
Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers (2018) (5)
Abstract 2396: IMA950: A novel multi-peptide cancer vaccine for treatment of glioblastoma (2010) (5)
Antigen recognition: Editorial overview Peptimmunology (1994) (5)
Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19 (2020) (5)
Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine (2007) (5)
Clearance of Chlamydia pneumoniae Infection in H‐2 Class I–/– Human Leucocyte Antigen‐A2.1 Monochain Transgenic Mice (2005) (5)
A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells. (2016) (5)
Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors (2020) (5)
From Basic Immunology to New Therapies for Cancer Patients (2014) (5)
Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues (2022) (5)
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade (2022) (4)
Identification of CD 70-mediated Apoptosis of Immune Effector Cells as a Novel Immune Escape Pathway of Human Glioblastoma 1 (2002) (4)
Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model (2022) (4)
CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity. (2000) (4)
The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence (2019) (4)
HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy (2013) (4)
Cell surface antigen Thy-1 (1989) (4)
Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups (2020) (4)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (4)
HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy (2016) (4)
Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation. (2016) (4)
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma (2022) (3)
Molecular cloning of a macrophage‐derived, interferon‐inducible secreted immunoglobulin‐binding protein (1999) (3)
A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex–Peptide Monomers by Flow Cytometry (2017) (3)
Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (3)
Association of major histocompatibility class II antigens with core subdomains present within human ocular drusen (2007) (3)
The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery. (2020) (3)
A MAGE-A 1 HLA-A * 0201 Epitope Identified by Mass Spectrometry 1 (2001) (3)
Antigen-presenting cells and the eye (2007) (3)
Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency (2022) (3)
Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial (2019) (3)
Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. (2020) (3)
The peptide-specific alloreactive human T cell repertoire varies largely between individuals and is not extended in HLA-A*0205--anti-HLA-A*0201 pairings. (2001) (3)
Protein-specific cytotoxic T lymphocytes. Recognition of transfectants expressing intracellular, membrane-associated or secreted forms of β-galactosidase (2006) (3)
Activation and Survival Responses: Differential Regulation of Cells-1 in Neutrophil Inflammatory Triggering Receptor Expressed on Myeloid (2004) (3)
Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma (2021) (3)
NKp 80 defines and stimulates a reactive subset of CD 8 T cells (2008) (3)
Dendritic Cells Pulsed with Protein or Selected Peptides T Effector Cells by + Generation of Survivin-specific CD 8 Updated (2000) (2)
BOTH PARENTS AS DONORS IN BONE MARROW TRANSPLANTATION? (1986) (2)
Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients (2019) (2)
Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion (2021) (2)
Chromatin-activated neutrophils represent a major source of interferon-α (2011) (2)
[Tumor vaccines-therapeutic vaccination against cancer]. (2020) (2)
Short-term oxaliplatin exposure according to established hyperthermic intraperitoneal chemotherapy (HIPEC) protocols lacks effectiveness in vitro and ex vivo (2019) (2)
iVacALL: utilizing next-generation sequencing for the establishment of an individual peptide vaccination approach for paediatric acute lymphoblastic leukaemia (2013) (2)
The Impact of Biomaterial Cell Contact on the Immunopeptidome (2020) (2)
miHA-Match: computational detection of tissue-specific minor histocompatibility antigens. (2012) (2)
Broad and Efficient Activation of Memory CD4+ T Cells by Novel HAdV- and HCMV-Derived Peptide Pools (2021) (2)
Single-chain Fv-based affinity purification of the cellular stress protein gp96 for vaccine development. (2003) (2)
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells. (2007) (2)
T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells (2022) (2)
NKG 2 D Ligand MICA theToll-Like Receptor-Induced Expression of Interaction of Monocytes with NK Cells upon (2008) (2)
Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells--a hypothesis. (1991) (2)
Differential expression of THELPER1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus‐specific T cells following re‐stimulation (2014) (1)
Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture (2020) (1)
Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC (2016) (1)
HLA Ligandome Analysis of Acute Myeloid Leukemia (AML) Revealed Novel Tumor-Associated Antigens for Immunotherapy. (2012) (1)
CMV infection not responding to antiviral chemotherapy specific T cells for the treatment of - Infusion of cytomegalovirus (CMV) (2013) (1)
Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches (2016) (1)
Adjuvant multipeptide vaccination in high-risk renal cell carcinoma. (2010) (1)
Antigen-specific suppression by veto cells (1985) (1)
History and Overview (1997) (1)
Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (1)
Introduction: MHC class I structure and function (1993) (1)
Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy (2015) (1)
Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)—Towards Peptide Based Immunotherapy (2014) (1)
Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC (2017) (1)
Author response for "SARS‐CoV‐2‐reactive T cell receptors isolated from convalescent COVID‐19 patients confer potent T cell effector function" (2021) (1)
From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia (2013) (1)
[The major histocompatibility complex and self and non-self differentiation through the immune system]. (1983) (1)
Patient-individual Antitumor Vaccines Integrated Functional Genomics Approach for the Design of Updated (2002) (1)
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma (2019) (1)
Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma (2016) (1)
In silico prediction of Leishmania major‐specific CD8+ epitopes (2017) (1)
MHC / Anti-CD 28-Coated Microspheres CalibratedHuman CD 8 T Cells Expanded on Cutting Edge : Predetermined Avidity of Rammensee and (2003) (1)
Correction to Supporting Information for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2015) (1)
An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl+ Cells. (2006) (1)
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival (2021) (1)
ORIGINAL ARTICLE Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia (2008) (1)
Recognition by Immune Cells (1997) (1)
Minimal structure of lipopeptides for in vivo priming of cytotoxic T-lymphocytes (1991) (1)
Characterization Of The HLA Class II Ligandome In Acute Myeloid Leukemia (AML) Reveals Novel Candidates For Peptide-Based Immunotherapy (2013) (1)
Mapping The HLA Ligandome Of Chronic Lymphocytic Leukemia – Towards Peptide Based Immunotherapy (2013) (1)
Abstract A170: The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines (2016) (1)
Abstract CT057: Phase I trial to evaluate the feasibility and safety of an individualized peptide vaccine of unmodified cancer antigens: PepIVAC-01 (2018) (1)
Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes1 (2006) (1)
BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells. (2009) (1)
Role for Ocular Antigen-Presenting Cells in Pigmentary Forms of Glaucoma (2007) (1)
Characterization of “Veto” Cells that Cause Nonresponsiveness to Minor Histocompatibility Antigens (1983) (1)
Abstract B144: Reduction of minimal residual disease in pediatric B-precursor acute lymphoblastic leukemia by an Fc-optimized CD19 antibody (2016) (1)
Integrin activation enables simultaneous and sensitive detection of functional virus-specific CD4+ and CD8+ T cells (2020) (1)
Structure and Function of MHC Class I Molecules (1993) (1)
Her-2 / neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes 1 (2006) (1)
The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome is Evolutionarily Conserved (2020) (1)
Identification of Naturally Presented HLA Ligands of Enriched Leukemic Progenitor Cells for Peptide-Based Immunotherapy in Acute Myeloid Leukemia (AML) (2016) (1)
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients. (2021) (1)
Identification of a novel cancer-testis antigen as a target for the immunotherapy of acute myeloid leukaemia (AML) (2009) (1)
Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide (2012) (1)
Expression of checkpoint receptors in tumor-infiltrated T-cells of renal cell and prostate carcinomas (2017) (1)
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients (2022) (1)
Author response: An open-source computational and data resource to analyze digital maps of immunopeptidomes (2015) (0)
Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules (2018) (0)
Wilms Tumor Protein-1-Derived 9-Mer Peptide Induces CD4 T-Cell Responses in an HLA-DR Restricted Manner (2012) (0)
Impact of the IDO2 blocker D-1-methyltryptophan on the IDO activity of human tumors and dendritic cells (2009) (0)
Susceptibility Differences Correlated with Disease Immuno-20 S Proteasomes Indicates Degradation by Constitutive and Quantitative Analysis of Prion-Protein and Hansjörg (2003) (0)
562. Human T-Cells Modified as Antigen Presenting Cells Are Superior to Professional APC in Stimulating T-Cell Responses (2004) (0)
Consequences of expression and release of MIC molecules by malignant cells. (2004) (0)
ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2018) (0)
Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by cytotoxic T-cells (1997) (0)
Development of a novel DNA vaccine encorporating a PASD1 analogue peptide which can enhance anti-leukaemia T cell responses in vitro and in vivo (2010) (0)
Therapeutic Mainpulation of Ocular Antigen-Presenting Cells in Corneal Transplantation (2007) (0)
potent primary in vitro induction memory T cells: artificial APCs pave the way for clinical application by specific CD8+ effector - Cytotoxic minor histocompatibility antigen HA-1 (2013) (0)
Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type (2015) (0)
Adjuvant to lnduzierung a cellular immune response (2016) (0)
Deciphering the AT/RT ligandome (2018) (0)
Synthetic vaccine for specifically inducing cytotoxic t-lymphocyte (1990) (0)
Tumorvakzinierung ; Tumor immunization. On the way to individualized treatment (2012) (0)
Krebsimmuntherapien : Standards und Innovationen; 61 Tab. (2008) (0)
GVHD protection and I-J: manifestations of specificity-related T-cell determinants. (1988) (0)
549 Results of a prospective phase I/II randomized trial of peptide-specific vaccination in HLA-A*0201 positive prostate carcinoma patients with biochemical recurrence after radical prostatectomy (2016) (0)
Lupus Erythematosus Pathway of Innate Immunity in Systemic Endocytosis of Nucleosomes Reveals a New Activation and Recruitment upon TLR2/TLR4-Independent Neutrophil (2006) (0)
On Memory T Lymphocytes: Heterogeneity of the Immunological Memory (2004) (0)
Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation. (2012) (0)
Serum Uric Acid Levels Can Serve As a Sensitive Biomarker for Immunologic Activity in Patients Undergoing Hematopoietic Cell Transplantation (2011) (0)
Intradermal intranodal vaccine with Protamin stabilizes mRNA coding for cancer associated antigen - immune response and clinical course in 14 patients with melanoma (2010) (0)
Procedure for identifying immunoreactive peptides. (2003) (0)
Development of therapeutic Peptide vaccines against Cancer (2012) (0)
Correction for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2015) (0)
Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers (2015) (0)
Obituary: Dr Zoltan A. Nagy (1941–2020) (2021) (0)
Influences of Transporter Associated with Antigen Processing (TAP) on the Repertoire of Peptides Associated with the Endoplasmic Reticulurn-resident Stress Protein gp96 By Dani~le Arnold, Claudia Wahl, Stefan Faath, (1997) (0)
Elevated Heat Shock Protein 70 (HSP70) Serum Levels After Tumor Radiofrequency Ablation Might Represent a Favorable Prognostic Marker. (2009) (0)
Abstract A112: Mapping the impact of proteasome inhibitor therapy on the antigenic landscape of multiple myeloma: Identifying robust targets for T cell immunotherapy (2016) (0)
The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy (2018) (0)
The Innate Immune System Favors Emergency Monopoiesis at the Expense of DC Differentiation to Control Bacterial Infections (2014) (0)
Peptides presented by HLA molecules and clinical applications (2000) (0)
A method of identifying or isolating a molecule, and thus identified molecules (1996) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Abstract 2291: On- and off target toxicity profiling for adoptive cell therapy by mass spectrometry-based immunopeptidome analysis of primary human normal tissues (2016) (0)
Retraction: Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma (Molecular & cellular proteomics : MCP (2018) 17 11 (2132-2145)) (2019) (0)
HLA-associated multipeptide vaccination in biochemically relapsed prostate cancer patients. (2009) (0)
3.3. Peptide Based Vaccines (1996) (0)
Antigen Presentation in the Eye: Uveitis (2007) (0)
[Individualized immunotherapy for malignant tumors using peptide vaccines-maybe it does work after all?] (2020) (0)
A peptide antigen MUC-1 DNA corresponding to elicit an immune response against tumor cells (2000) (0)
Epinephrine suppresses integrin activity of stimulated cytomegalovirus-specific T cells in healthy humans (2016) (0)
Subject Index Vol. 110, 1996 (1996) (0)
MelanomaTumor-Reactive CTL Infiltrating Metastatic SSX-2-Derived Epitope Recognized by Proteasome-Assisted Identification of a (2002) (0)
CHAPTER 50 – Cancer Vaccines: Some Basic Considerations (2009) (0)
Presentation of MHC I-restricted self peptides in kidney carcinoma cells (2007) (0)
Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis – New Targets for Peptide Based Immunotherapy (2012) (0)
IMMU-28. DECIPHERING THE AT/RT LIGANDOME (2018) (0)
Corneal Antigen-Presenting Cells: What Have We Learned from Transplantation? (2007) (0)
HLA ligandome analysis of different hematological malignancies identifies a small panel of naturally presented 'pan-leukemia' antigens (2016) (0)
48: Peptide-based immunotherapy of cancer (2014) (0)
Global Analysis of the Mammalian MHC class I Immunopeptidome at the Organism-Wide Scale (2020) (0)
Abstract # 1813 G-alpha-s-protein coupled receptor signaling suppresses integrin-mediated cell adhesion of antigen-specific human CD8+ T cells (2016) (0)
Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and human papilloma virus status in head and neck squamous cell carcinoma. (2018) (0)
Corrigendum to “Characterization of an HIV-1 p24gag epitope recognized by a CD8+ cytotoxic T-cell clone” (2001) (0)
Procedure for the identification or isolation of a molecule and molecules identified thereby. (1996) (0)
IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY (2019) (0)
Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives (2016) (0)
Applied Tumor Virology (1995) (0)
Abstract B057: Optimizing the high throughput in vitro priming of tumor specific T cells (2016) (0)
G-alpha-s-coupled receptor signaling controls circadian rhythm in integrin-mediated cell adhesion of virus-specific human CD8+ T cells (2016) (0)
Graft versus Host Disease of the retina and recognition of self-antigens after allogeneic hematopoietic cell transplantation (2015) (0)
P06.05 The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T-cell based immunotherapy (2017) (0)
Identification and Characterization of T-Cell Epitopes Deduced from RGS 5 , a Novel Broadly ExpressedTumorAntigen (2007) (0)
IMMU-28. THE INTRA-TUMORAL SPATIAL HETEROGENEITY OF T CELL ANTIGENS IN GLIOBLASTOMA: AN INTEGRATED MULTI-OMICS APPROACH (2022) (0)
Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas (2022) (0)
Abstract 3556: Immunopeptidomics-guided tumor antigen warehouse design and first clinical application of a personalized peptide vaccine for prostate cancer (2022) (0)
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (0)
New and potent MHC class II peptides derived from survivin (2009) (0)
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia (2017) (0)
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro (2023) (0)
Disulfide-stabilized recombinant MHC class I molecules allow the generation of peptide-receptive MHC tetramers (2022) (0)
Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides (2022) (0)
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy (2020) (0)
HLA-ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma (2019) (0)
HLA-Tetramer Selection Peptide-Selective Alloreactive T Cells Using Cutting Edge : Characterization of Allorestricted and (2001) (0)
Abstract A113: iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants (2016) (0)
A fast live-cell assay to detect antigen-specific CD8+ T cells based on upregulation of integrin-mediated adhesion (2016) (0)
Abstract A113: iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants (2016) (0)
OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial (2018) (0)
Cancer Immunotherapy Meets Oncology (2014) (0)
O75 - Motif for HLA-DQ2 (α1*0501, β1*0201): Evidence for anchors at positions one, four, six, seven and nine (1996) (0)
IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases (2022) (0)
Abstract 1375: The intra-tumoral spatial heterogeneity of T-cell antigens in glioblastoma: An integrated multi-omics approach (2022) (0)
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma (2020) (0)
Pre-clinical and Early Clinical Experience Using Dendritic Cells to Treat Human Malignancy (1999) (0)
Antigen Presentation by Human Leukocyte Antigen Molecules— One of the Keys for Understanding the Etiology of Autoimmune Disease? (2007) (0)
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition (2020) (0)
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination (2023) (0)
Peptidase II Involvement Tripeptidyl 1 MHC Class I Epitopes Requires Processing of Two Latent Membrane Protein (2009) (0)
Immunological characterization of naturally presented non-mutant CML-associated HLA ligands reveals novel CD8(+) and CD4(+) T cell epitopes for immunotherapeutic approaches (2017) (0)
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity (2021) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity (2021) (0)
Human peripheral Vδ1+ γδ T cells can develop into αβ T cells (P4460) (2013) (0)
Gs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells (2019) (0)
Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells (2023) (0)
Effective Chemokine Secretion by Dendritic Cells and Expansion of Cross-Presenting CD4 (cid:2) /CD8 (cid:1) Dendritic Cells Deﬁne a Protective Phenotype in the Mouse Model of Coxsackievirus Myocarditis (cid:1) (2008) (0)
Peptide to induce an immune response against tumor cells containing them pharmzeutische compositions, uses thereof, nucleic acid coding therefor and these nucleic acid expression vector containing (1999) (0)
Abstract 2008: The oncogenic fusion protein DNAJB1-PRKACA can be actively targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma (2022) (0)
Correction: Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry (Vol. 34(12) 2004, p. 3644-3651) (2005) (0)
Of volatiles and peptides: in search for MHC-dependent olfactory signals in social communication (2014) (0)
Differential host response to a herpesvirus: Marek’s disease virus peptides on chicken MHC class II molecules are derived from only a few genes and illustrate a new mode of peptide binding (2020) (0)
Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome (2018) (0)
How the quest to identify minor histocompatibility antigens led to something more important. (1994) (0)
Abstract 3168: Immunopeptidome-defined acute myeloid leukemia progenitor cell-associated antigens are targeted in vivo by AML patients’ T cells (2022) (0)
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (0)
A proliferation assay to determine specific T-cell immunity using HLA I-binding peptides (1995) (0)
Abstract 1991: Characterization of the exome, transcriptome, and immunopeptidome to map alterations in primary and recurrent glioblastoma (2022) (0)
Peptide-Specific Human CTL Alloreactivity as a Source of High Avidity (1998) (0)
β2-Microglobulin and β-Galactosidase: A Real and a Surrogate Minor Histocompatibility Antigen (1988) (0)
Control of Self Reactive CTL Independent of Thymic Selection (1987) (0)
PO-1292: Radiation planning parameters correlate with peripheral immune status during prostate radiotherapy (2020) (0)
Self-Peptide Recognition of Posterior Eye Segment Epitopes Mediated By Allogeneic T Cells in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (2014) (0)
Monoclonal and Bispecific Antibodies as Novel Therapeutics (2005) (0)
Medium containing a complex of a polymeric mediator, and a peptide, as well as a support surface for the adsorptive binding of the complex (1995) (0)
Immunogenic T-helper epitopes of human tumor antigens and their use in immunotherapeutic methods (2004) (0)
Matrilysin ( MMP-7 ) Is a Novel Broadly ExpressedTumorAntigen Recognized byAntigen - (2008) (0)
Sequence Motifs of Peptides Eluted from MHC Molecules are Allele Specific (1992) (0)
Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity (2013) (0)
Abstract B104: Characterization and specificity analysis of tumor infiltrating lymphocytes in ovarian carcinoma (2016) (0)
Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC (2016) (0)
Elimination of self-reactive CD8+, but not CD4+, T cells by a peripheral immune mechanism. (1990) (0)
Correction (2020) (0)
HLA Ligandome Profiling Identifies a Novel Category of Pathophysiologically Relevant CLL Associated Antigens (2014) (0)
HLA Ligandome Analysis in Multiple Myeloma Reveals Novel Naturally Presented Myeloma-Associated Antigens Showing Stable Expression Under Proteasome Inhibitor Therapy (2014) (0)
Identification of RGS5 as a tumor-associated antigen expressed in a broad range of human malignancies and recognized by antigen specific cytotoxic T cells. (2006) (0)
HLA Ligandome Analysis in Primary Polycythemia Vera (PV) Samples Shows No Tumor-Association of Naturally Presented JAK2 Ligands but Reveals a Vast Array of Novel PV-Associated HLA Ligands (2014) (0)
Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies (2011) (0)
synthetic vaccine for the induction of specific cytotoxic T lymphocytes. (1990) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
762 Results of a phase I/II study in metastatic renal cell carcinoma patients treated with an adjuvant HLA personalized peptide vaccine after resection of metastases and comparison to a contemporary cohort of patients with mRCC (2016) (0)
Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations (2016) (0)
An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens (2020) (0)
Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage (2016) (0)
Muc-1 peptide antigen to trigger an immune reaction against tumor cells. (2000) (0)
Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma (2019) (0)
Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival (2013) (0)
Peptide motif and its use (1991) (0)
Interaction of the immunodominant MBP peptide 87-106 with multiple sclerosis-associated HLA DR- and -DQ molecules (1994) (0)
Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC (2016) (0)
246 SPECIFIC CD4+ AND CD8+ T CELLS ACTIVATION BY MULTI-PEPTIDE VACCINATION IN PATIENTS WITH STAGE III RENAL CELL CARCINOMA (2011) (0)
Consequences MyD88-Independent Pathway: Direct Dendritic Cell Activation via a Systemic Lupus Erythematosus, Induces Nucleosome, the Main Autoantigen in (2013) (0)
Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia (2012) (0)
ANALYSIS OF THE T CELL RESPONSE TO MELANOMA-ASSOCIATED PEPTIDE EPITOPES IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF MELANOMA PATIENTS AND HEALTHY DONERS BY AN ELISPOT ASSAY (1996) (0)
HLA Class I Ligandome Analysis In Acute Myeloid Leukemia – Novel T-Cell Epitopes For Peptide-Based Immunotherapy (2013) (0)
Analysis of the Multiple Myeloma HLA Peptidome Identifies a Naturally Presented Bcma-Derived Peptide As an Immunogenic T-Cell Epitope for Immunotherapeutic Approaches (2018) (0)
PMHC ARRAYS DEMONSTRATE THAT "UNTOUCHED" T CELL POPULATIONS FROM PRESENTATION ACUTE MYELOID LEUKAEMIA PATIENTS PREDOMINANTLY RECOGNIZE THE CANCER-TESTIS ANTIGEN, PASD1 (2013) (0)
Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen. (2006) (0)
Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy (2015) (0)
HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of Pan-Leukemia-Associated Antigens (2016) (0)
The veto concept (1985) (0)
On the development of personalized cancer vaccines (2018) (0)
Binding to MHC molecules, tumor-associated peptides (2003) (0)
Chromatin-activated neutrophils represent a major source of interferon α (2011) (0)
Human Peripheral CD34+ γδ T Cells Can Transdifferentiate into αβ T Cells. (2012) (0)
Radiofrequency Ablation of Liver Metastases from Colorectal Cancer Induces a Cancer-Specific T Cell Repertoire in Humans (2018) (0)
A process for the identification and isolation of a molecule and recognized by this molecule (1996) (0)
TLR9-independent and immune complex-independent interferon α production by neutrophils upon netosis in response to circulating chromatin (2012) (0)
OP0255 TLR9-independent and immune complex-independent interferon-alpha production by neutrophils upon netosis in response to circulating chromatin (2013) (0)
Contents, Vol. 110, 1996 (1996) (0)
Abstract SY27-03: Biomarker-guided development of novel multi-peptide cancer vaccines - from discovery to phase lll trials. (2013) (0)
Unexpected Abundance of HLAClass II Presented Peptides in Primary Renal Cell Carcinomas (2006) (0)
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome (2021) (0)
Universitet Gs-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells (2019) (0)

This paper list is powered by the following services:

Other Resources About Hans-Georg Rammensee

What Schools Are Affiliated With Hans-Georg Rammensee?

Hans-Georg Rammensee is affiliated with the following schools:

Hans-Georg Rammensee's Academic­Influence.com Rankings

Hans-Georg Rammensee's Degrees

Why Is Hans-Georg Rammensee Influential?

Hans-Georg Rammensee's Published Works

Published Works

Other Resources About Hans-Georg Rammensee

What Schools Are Affiliated With Hans-Georg Rammensee?

Image Attributions

Hans-Georg Rammensee's AcademicInfluence.com Rankings